- cafead Jun 05, 2021 at 02:43: PM
via Just less than a year ago, Gilead’s Kite won a landmark okay for its second CAR-T therapy, with data that former head of global development Ken Takeshita hailed as “better than Yescarta.” Now, ahead of #ASCO21, Kite is unveiling pivotal data to back the drug in a new type of cancer.
article source
article source